Blog
RSS FeedPosted by Michael Wonder on 27 Apr 2023
CADTH formalises offering on real-world evidence through its scientific advice program
25 April 2023 - During a 1-year learning period, CADTH expanded its Scientific Advice program to include advice on real-world evidence ...
Posted by Michael Wonder on 18 Apr 2023
AbbVie announces provincial reimbursement for Vraylar (cariprazine) for the treatment of schizophrenia in Québec
17 April 2023 - AbbVie today announced that Vraylat is now listed as an exception medication status on the list of ...
Posted by Michael Wonder on 02 Apr 2023
Mitsubishi Tanabe Pharma Canada receives engagement letter from Pan-Canadian Pharmaceutical Alliance for Radicava oral suspension
31 March 2023 - Mitsubishi Tanabe Pharma Canada is pleased to announce the company has entered into negotiations with the ...
Posted by Michael Wonder on 23 Mar 2023
Investments to support access to drugs for rare diseases
22 March 2023 - Today, the Government announced a total investment of up to $1.5 billion over three years in ...
Posted by Michael Wonder on 23 Mar 2023
Government of Canada improves access to affordable and effective drugs for rare diseases
22 March 2023 - Today, the Honourable Jean-Yves Duclos, Minister of Health, announced measures in support of the first-ever National Strategy ...
Posted by Michael Wonder on 20 Mar 2023
Resignations at Canada’s drug pricing panel raise independence questions
14 March 2023 - A member of Canada’s drug pricing regulator has resigned, stating the federal government has undermined the ...
Posted by Michael Wonder on 19 Mar 2023
Lower drug prices are a good thing. Canada’s approach to achieving them was not.
17 March 2023 - Over the past six years, the Patented Medicine Prices Review Board – Canada’s federal drug-price regulating agency ...
Posted by Michael Wonder on 10 Mar 2023
Alberta’s import of children’s medication to cost taxpayers $80 million
9 March 2023 - Alberta taxpayers are on the hook for $80 million, after Health Minister Jason Copping finally revealed ...
Posted by Michael Wonder on 09 Mar 2023
CADTH recommends reimbursement for BioCryst’s Orladeyo (berotralstat) for the routine prevention of attacks in hereditary angioedema patients in Canada
8 March 2023 - BioCryst Pharmaceuticals today announced that the CADTH Canadian Drug Expert Committee has issued a positive recommendation ...
Posted by Michael Wonder on 03 Mar 2023
Health minister disputes claim he sided with big pharma, interfered with drug price consultations
1 March 2023 - Review board 'will never be subjected to political interference,' Duclos said. ...
Posted by Michael Wonder on 01 Mar 2023
The drug prices review board was once a solution. It’s now a problem.
1 March 2023 - Anti-drug company activists are repeating ill-informed myths about controlling drug prices in Canada. ...
Posted by Michael Wonder on 24 Feb 2023
Member of Canada’s drug pricing regulator quits over ‘lack of support’ for medicine cost reforms
23 February 2023 - A member of the Patented Medicine Prices Review Board, Canada’s drug pricing regulator, has resigned over ...
Posted by Michael Wonder on 07 Feb 2023
Valeo Pharma obtains public reimbursement for Onstryv in Quebec
7 February 2023 - Quebec public reimbursement coverage to facilitate and expand medication access for Parkinson’s patients in Quebec. ...
Posted by Michael Wonder on 02 Feb 2023
Medexus secures public reimbursement for Cuvposa in Quebec
1 February 2023 - Medexus Pharmaceuticals wishes to inform investors that the company has reached an agreement with the provincial government ...
Posted by Michael Wonder on 19 Jan 2023
Radicava (edarvarone) oral suspension receives positive recommendation from CADTH for the treatment of patients with ALS
18 January 2023 - Mitsubishi Tanabe Pharma Canada is pleased to announce a positive recommendation from the CADTH Canadian Drug Expert ...